个体化缩短弹力压迫治疗时长与标准时长预防血栓后综合征的成本效果分析
基于IDEAL DVT多中心随机非劣效试验,纳入865例急性近端下肢深静脉血栓患者,比较根据Villalta评分个体化缩短弹力袜压迫时长与标准2年方案的成本效果。
要点
- 个体化缩短弹力压迫治疗时长较标准2年方案具有成本效果。
- 每QALY 30000欧元阈值下个体化策略具成本效果的概率为99%。
核心结论
- 个体化缩短弹力压迫治疗时长与标准时长弹力压迫治疗相比具有成本效果。
- 采用个体化弹力袜压迫治疗预防深静脉血栓后血栓后综合征可在不损失健康相关生活质量的情况下大幅节约成本。
研究设计与样本
- IDEAL DVT为多中心、随机、非劣效试验,纳入急性近端下肢深静脉血栓患者。
- 弹力压迫治疗6个月后按1:1随机分配至标准2年弹力袜压迫治疗或基于患者Villalta评分缩短压迫时长。
- 成本效果分析按意向性治疗原则评估QALYs(EQ-5D-3L荷兰与英国效用值、SF-36)及成本(欧元,卫生保健与社会视角)。
- 数据在血栓诊断后3、6、12、24个月收集;采用每QALY 30000欧元阈值计算增量净货币效益,并获得自助法均值和95%CI。
- 2011年3月22日至2015年7月1日共纳入865例患者,437例分配至个体化时长组,428例分配至标准时长组。
主要发现
- 9例患者因首次事件后6个月内复发静脉血栓栓塞最终被排除。
- 使用EQ-5D英国效用值,个体化策略更有效且成本更低(4071欧元,95%CI 1452-6647)。
- 在每QALY 30000欧元阈值下(EQ-5D荷兰效用值),个体化策略具成本效果的概率为99%。
关键数值与推荐
- 增量净货币效益采用每QALY 30000欧元阈值计算。
- EQ-5D荷兰效用值下增量净货币效益3205欧元(95%CI 502-5741)。
- SF-6D效用值得分下增量净货币效益3540欧元(95%CI 1174-5953)。
- EQ-5D英国效用值下增量净货币效益4071欧元(95%CI 1452-6647)。
临床怎么用
- 作者认为,采用个体化弹力袜压迫治疗预防深静脉血栓后血栓后综合征可在不损失健康相关生活质量的情况下大幅节约成本。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The IDEAL DVT study showed that it was safe to shorten the duration of elastic compression therapy on an individualised basis after deep vein thrombosis for prevention of post-thrombotic syndrome. In this study, we assessed the cost-effectiveness of this strategy. METHODS: IDEAL DVT was a multicentre, randomised, non-inferiority trial that included patients with acute proximal deep vein thrombosis of the leg. After 6 months of elastic compression therapy, patients were randomly assigned (1:1) to the standard 2 years of elastic stocking compression therapy or shortened duration of compression therapy based on the patient's Villalta score. For our cost-effectiveness analysis, we assessed quality-adjusted life-years (QALYs), measured with the three-level version of EQ-5D (EQ-5D-3L; Dutch and UK tariff) and the 36-item Short Form Health Survey (SF-36), and costs in € (health-care and societal perspective) according to the intention-to-treat approach. Data were collected at 3, 6, 12, and 24 months after diagnosis of thrombosis. We calculated incremental net monetary benefit using a QALY threshold of €30 000, and obtained bootstrapped means and 95% CIs. IDEAL DVT is registered with ClinicalTrials.gov, number NCT01429714. FINDINGS: Between March 22, 2011, and July 1, 2015, 865 patients were enrolled in IDEAL DVT. 437 were assigned to individualised duration of elastic compression therapy and 428 to standard duration of elastic compression therapy. Nine patients were eventually excluded because of recurrent venous thromboembolism within 6 months after the first event. From a societal perspective, for every QALY lost measured with the EQ-5D Dutch tariff, cost savings were €305·992 (incremental net monetary benefit €3205, 95% CI 502-5741), and for every QALY lost based on the Short-Form Six-Dimension (SF-6D) utility score (derived from SF-36), cost savings were €6030·941 (€3540, 95% CI 1174-5953). Using the UK tariff for EQ-5D, the individualised strategy was more effective and less costly (€4071, 1452-6647). The probability that the individualised strategy was cost-effective was 99% at a threshold of €30 000 per QALY (EQ-5D Dutch tariff). INTERPRETATION: Individually shortened duration of elastic compression therapy was cost-effective compared with standard duration elastic compression therapy. Use of an individualised approach to elastic stocking compression therapy for the prevention of post-thrombotic syndrome after deep vein thrombosis could lead to substantial costs savings without loss in health-related quality of life. FUNDING: Netherlands Organisation for Health Research and Development.
引用
- Amin EE, Ten Cate-Hoek AJ, Bouman AC, et al. Individually shortened duration versus standard duration of elastic compression therapy for prevention of post-thrombotic syndrome: a cost-effectiveness analysis. Lancet Haematol. 2018. PMID: 30314712. doi:10.1016/S2352-3026(18)30151-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。